Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133396) titled 'Efficacy and Safety of Idarubicin-TACE Sequentially Followed by FOLFOX Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Early Intrahepatic Recurrent Hepatocellular Carcinoma After Liver Transplantation' on Sept. 24.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shulan (Hangzhou) Hospital
Condition:
Intrahepatic recurrent hepatocellular carcinoma within 12 months after liver transplantation
Intervention:
Dual-combination treatment group (IDA-TACE plus lenvatinib):none
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-02
Target Sampl...